Tadah Forte is a light yellow to yellow circular film-coated tablet, biconvex, quadrisect on one side and plain on the other side.
Each film-coated tablet contains: Tadalafil 20 mg.
Pharmacology: Pharmacodynamics: Tadalafil is a selective phosphodiesterase 5 (PDE5) inhibitor. PDE5 regulates nitric oxide-mediated vasodilatation through degradation of the second messenger cGMP and is abundantly expressed in lung tissue. Nitric oxide treatment involves the continuous insulation of nitric oxide to widen blood vessels in the lungs. It is given by mouth as the citrate although doses are expressed in terms of the base.
Pharmacokinetics: Tadalafil is well absorbed after dose by mount. Peak plasma concentrations are attained within 2 hours; the rate and extent of absorption are not affected by food. Tadalafil is widely distributed into tissues and is about 94% bound to plasma proteins. It is metabolized in the liver mainly by the cytochrome P450 isoenzyme CYP3A4. The mean half-life of Tadalafil is about 17.5 hours. Tadalafil is excreted, mainly as metabolites, in the feces (61% of the dose), and to a lesser extent urine (36% of the dose). Clearance may be reduced in the elderly and in patients with renal impairment.
It is used in the management of erectile dysfunction.
20 mg once daily, taken as early as 30 minutes prior to sexual activity or as prescribed by the physician.
Single doses up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses. In cases of overdose, standard supportive measures should be adopted as required. Hemodialysis contributes negligibly to Tadalafil elimination.
Known hypersensitivity to Tadalafil or any ingredient in the formulation; concomitant use of any form of organic nitrates (e.g., nitrates, nitrites, or nitric oxide donors); should not be used in men whom sexual activity is inadvisable of their underlying cardiovascular status.
The cardiovascular risks of sexual activity should be considered before beginning therapy with Tadalafil. Caution is required in patients with hepatic or severe renal impairment and dosage reduction may be necessary. Care is also needed in patients with anatomical or hematological disorders which may predispose them to priapism. Patients who experience dizziness or visual disturbances should not drive or operate hazardous machinery.
Adverse effects most commonly reported from Tadalafil are headache, flushing and dyspepsia. There may be visual disturbances, dizziness and nasal congestion. Other adverse effects reported include diarrhea, muscle pain, skin rashes and urinary or respiratory tract infections. Priapism has also occurred. There have also been reports of serious cardiovascular events, including sudden cardiac death, associated with the use of Tadalafil.
Tadalafil may potentiate the hypotensive effects of organic nitrates, and is therefore contraindicated in patients receiving such drugs. Concomitant administration of Tadalafil with drugs that inhibits the cytochrome P450 isoenzyme CYP3A4 such as cimetidine, erythromycin, itraconazole, ketoconazole, and HIV-protease inhibitors may reduce Sildenafil clearance necessitating a reduction in dosage. However, plasma concentrations of Tadalafil are significantly increased by ritonavir, requiring even greater dosage reduction, and is therefore strongly recommended that these two drugs are not given together.
Store at temperatures not exceeding 30°C.
G04BE08 - tadalafil ; Belongs to the class of drugs used in erectile dysfunction.
Tadah Forte FC tab 20 mg
2's
Sign Out
